P. Hemachandra Reddy
#120,411
Most Influential Person Now
Neurology and Neuroscience/Pharamacology researcher
P. Hemachandra Reddy's AcademicInfluence.com Rankings
P. Hemachandra Reddymedical Degrees
Medical
#1822
World Rank
#2199
Historical Rank
Pharmacology
#173
World Rank
#212
Historical Rank
Neurology
#169
World Rank
#238
Historical Rank
P. Hemachandra Reddybiology Degrees
Biology
#7262
World Rank
#10157
Historical Rank
Neuroscience
#916
World Rank
#955
Historical Rank
Download Badge
Medical Biology
Why Is P. Hemachandra Reddy Influential?
(Suggest an Edit or Addition)P. Hemachandra Reddy's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. (2006) (1043)
- Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. (2008) (812)
- Mitochondrial dysfunction and oxidative stress in metabolic disorders - A step towards mitochondria based therapeutic strategies. (2017) (623)
- Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. (2011) (610)
- Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. (2011) (486)
- Role of Glutamate and NMDA Receptors in Alzheimer's Disease. (2017) (473)
- Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. (2010) (400)
- Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease. (2017) (364)
- Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. (2017) (344)
- Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. (2005) (341)
- Amyloid precursor protein‐mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer's disease (2006) (337)
- Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. (2011) (326)
- Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage. (2012) (323)
- Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-d-aspartate Receptors via Post-synaptic Density 95* (2001) (316)
- Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. (2012) (310)
- Differential expression of oxidative phosphorylation genes in patients with Alzheimer’s disease (2007) (307)
- Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. (2004) (306)
- Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. (2012) (303)
- Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases (2011) (299)
- Are mitochondria critical in the pathogenesis of Alzheimer's disease? (2005) (276)
- Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics. (2011) (253)
- Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease (2011) (241)
- Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease (2009) (240)
- Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. (2012) (238)
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial (2021) (229)
- Mitochondrial division ensures the survival of postmitotic neurons by suppressing oxidative damage (2012) (225)
- Is multiple sclerosis a mitochondrial disease? (2009) (223)
- Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons. (2017) (214)
- Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. (2010) (213)
- Are circulating microRNAs peripheral biomarkers for Alzheimer's disease? (2016) (212)
- Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. (2011) (205)
- Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease (2019) (199)
- Mitochondrial Medicine for Aging and Neurodegenerative Diseases (2008) (197)
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial (2021) (188)
- Mitochondria as a therapeutic target for aging and neurodegenerative diseases. (2011) (186)
- Time‐course of mitochondrial gene expressions in mice brains: implications for mitochondrial dysfunction, oxidative damage, and cytochrome c in aging (2005) (176)
- Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. (2007) (171)
- Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimer’s disease (2018) (168)
- Mitochondrial division and fusion in metabolism. (2015) (166)
- Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer's Disease. (2018) (165)
- Mutant APP and amyloid beta-induced defective autophagy, mitophagy, mitochondrial structural and functional changes and synaptic damage in hippocampal neurons from Alzheimer’s disease (2018) (162)
- Mitochondria-targeted catalase reduces abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension. (2012) (161)
- Stroke, Vascular Dementia, and Alzheimer's Disease: Molecular Links. (2016) (160)
- Dynamics of diabetes and obesity: Epidemiological perspective. (2017) (152)
- Can herbs provide a new generation of drugs for treating Alzheimer's disease? (2005) (150)
- Neuronal protection by sirtuins in Alzheimer's disease (2006) (148)
- MicroRNAs as Peripheral Biomarkers in Aging and Age-Related Diseases. (2017) (147)
- Mitochondrial structural and functional dynamics in Huntington's disease (2009) (147)
- Hippocampal phosphorylated tau induced cognitive decline, dendritic spine loss and mitochondrial abnormalities in a mouse model of Alzheimer’s disease (2018) (145)
- Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. (2012) (144)
- Mitochondrial Oxidative Damage in Aging and Alzheimer's Disease: Implications for Mitochondrially Targeted Antioxidant Therapeutics (2006) (139)
- Reduced dynamin-related protein 1 protects against phosphorylated Tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease. (2016) (125)
- Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease. (2016) (123)
- Therapeutics of Neurotransmitters in Alzheimer's Disease. (2017) (118)
- Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial (2021) (115)
- MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease (2017) (115)
- Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis. (2016) (111)
- Role of Mitochondria in Neurodegenerative Diseases: Mitochondria as a Therapeutic Target in Alzheimer's Disease (2009) (110)
- Mitochondrial Dysfunction and Oxidative Stress in Asthma: Implications for Mitochondria-Targeted Antioxidant Therapeutics (2011) (105)
- Inhibitors of mitochondrial fission as a therapeutic strategy for diseases with oxidative stress and mitochondrial dysfunction. (2014) (104)
- A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer's disease. (2017) (104)
- Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer's disease (2016) (104)
- Synaptic basis of Alzheimer’s disease: Focus on synaptic amyloid beta, P-tau and mitochondria (2020) (104)
- Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer's disease: implications for synaptic dysfunction and neuronal damage. (2013) (102)
- Peripheral biomarkers of stroke: Focus on circulatory microRNAs. (2016) (97)
- Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington's disease. (2016) (96)
- Mitochondrial division inhibitor 1 reduces dynamin-related protein 1 and mitochondrial fission activity (2018) (93)
- Defective mitophagy in Alzheimer’s disease (2020) (92)
- Dynamics of Dynamin-Related Protein 1 in Alzheimer’s Disease and Other Neurodegenerative Diseases (2019) (87)
- Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission. (2014) (82)
- Small molecules as therapeutic drugs for Alzheimer's disease (2019) (81)
- MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. (2013) (80)
- Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models (2006) (78)
- MicroRNA-455-3p as a Potential Biomarker for Alzheimer's Disease: An Update (2018) (77)
- Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer's disease? (2013) (73)
- Mitochondria-Division Inhibitor 1 Protects Against Amyloid-β induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer's Disease. (2017) (69)
- Abnormal interaction of oligomeric amyloid-β with phosphorylated tau: implications to synaptic dysfunction and neuronal damage. (2013) (68)
- Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington’s disease (2003) (68)
- Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer’s disease (2017) (66)
- Defective Autophagy and Mitophagy in Aging and Alzheimer’s Disease (2021) (65)
- Impact of COVID-19 on Mitochondrial-Based Immunity in Aging and Age-Related Diseases (2021) (64)
- Lifestyle Modifications and Nutritional Interventions in Aging-Associated Cognitive Decline and Alzheimer’s Disease (2020) (63)
- Are microRNAs true sensors of ageing and cellular senescence? (2017) (61)
- SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets (2020) (60)
- Mitochondrial division inhibitor 1 protects against mutant huntingtin-induced abnormal mitochondrial dynamics and neuronal damage in Huntington's disease. (2015) (60)
- Molecular Basis of Alzheimer's Disease: Focus on Mitochondria. (2019) (59)
- Mitochondria-Targeted Antioxidant SS31 Prevents Amyloid Beta-Induced Mitochondrial Abnormalities and Synaptic Degeneration in Alzheimer’s Disease (2012) (58)
- Amyloid Beta and MicroRNAs in Alzheimer’s Disease (2019) (58)
- Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives. (2022) (57)
- MicroRNAs, Aging, Cellular Senescence, and Alzheimer's Disease. (2017) (55)
- Synergistic Protective Effects of Mitochondrial Division Inhibitor 1 and Mitochondria-Targeted Small Peptide SS31 in Alzheimer's Disease. (2018) (53)
- CART Peptide Is a Potential Endogenous Antioxidant and Preferentially Localized in Mitochondria (2012) (53)
- Reduced VDAC1 protects against Alzheimer's disease, mitochondria, and synaptic deficiencies. (2013) (52)
- Assessment of newly synthesized mitochondrial DNA using BrdU labeling in primary neurons from Alzheimer's disease mice: Implications for impaired mitochondrial biogenesis and synaptic damage. (2011) (51)
- Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease. (2009) (50)
- Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial (2021) (50)
- Identification of novel circulatory microRNA signatures linked to patients with ischemic stroke (2018) (49)
- Dynamin-related protein 1 heterozygote knockout mice do not have synaptic and mitochondrial deficiencies. (2012) (49)
- P3-291 Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage (2004) (48)
- Emerging role of non‐coding RNA in health and disease (2021) (48)
- Novel MicroRNA-455-3p and its protective effects against abnormal APP processing and amyloid beta toxicity in Alzheimer's disease. (2019) (47)
- Autophagy in the diabetic heart: A potential pharmacotherapeutic target in diabetic cardiomyopathy (2021) (45)
- Defective mitophagy and synaptic degeneration in Alzheimer's disease: Focus on aging, mitochondria and synapse. (2021) (44)
- Therapeutic Strategies for Mitochondrial Dysfunction and Oxidative Stress in Age-Related Metabolic Disorders. (2017) (43)
- Structure Based Design and Molecular Docking Studies for Phosphorylated Tau Inhibitors in Alzheimer’s Disease (2019) (43)
- Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics (2020) (40)
- Aqua-soluble DDQ reduces the levels of Drp1 and A&bgr; and inhibits abnormal interactions between A&bgr; and Drp1 and protects Alzheimer’s disease neurons from A&bgr;- and Drp1-induced mitochondrial and synaptic toxicities (2017) (38)
- Molecular Links and Biomarkers of Stroke, Vascular Dementia, and Alzheimer's Disease. (2017) (36)
- Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease. (2019) (36)
- Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal. (2017) (34)
- Mitochondrial MicroRNAs in Aging and Neurodegenerative Diseases (2020) (34)
- Toxicity of Neurons Treated with Herbicides and Neuroprotection by Mitochondria-Targeted Antioxidant SS31 (2011) (34)
- A New Discovery of MicroRNA-455-3p in Alzheimer's Disease. (2019) (33)
- Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic (2021) (32)
- Can Healthy Diets, Regular Exercise, and Better Lifestyle Delay the Progression of Dementia in Elderly Individuals? (2019) (30)
- RNA silencing of genes involved in Alzheimer's disease enhances mitochondrial function and synaptic activity. (2013) (30)
- The COVID-19 Effect on the Immune System and Mitochondrial Dynamics in Diabetes, Obesity, and Dementia (2020) (28)
- Protective effects of mitophagy enhancers against amyloid beta-induced mitochondrial and synaptic toxicities in Alzheimer disease. (2021) (28)
- The role of synaptic microRNAs in Alzheimer's disease. (2020) (28)
- A Critical Assessment of Research on Neurotransmitters in Alzheimer's Disease. (2017) (27)
- Abnormal interaction of VDAC 1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer ’ s disease (2012) (27)
- Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection (2020) (26)
- Can Diabetes Be Controlled by Lifestyle Activities? (2017) (26)
- DNA repair fidelity in stem cell maintenance, health, and disease. (2020) (25)
- Maternal exercise upregulates mitochondrial gene expression and increases enzyme activity of fetal mouse hearts (2017) (24)
- Non-Coding RNAs Based Molecular Links in Type 2 Diabetes, Ischemic Stroke, and Vascular Dementia. (2020) (24)
- Liquid Crystals: A Novel Approach for Cancer Detection and Treatment (2018) (24)
- Novel miRNA PC-5P-12969 in Ischemic Stroke (2019) (23)
- Mitochondrial DNA deletions and differential mitochondrial DNA content in Rhesus monkeys: implications for aging. (2012) (21)
- Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report (2020) (21)
- Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19 (2020) (21)
- COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges (2021) (21)
- Molecular and cellular bases of diabetes: Focus on type 2 diabetes mouse model-TallyHo. (2019) (20)
- Deregulated mitochondrial microRNAs in Alzheimer's disease: Focus on synapse and mitochondria (2021) (20)
- Neurotransmitter CART as a New Therapeutic Candidate for Parkinson’s Disease (2013) (20)
- Protective Effects of Anti-depressant Citalopram Against Abnormal APP Processing and Amyloid Beta-induced Mitochondrial Dynamics, Biogenesis, Mitophagy and Synaptic Toxicities in Alzheimer's Disease. (2021) (20)
- The Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer’s Disease (2021) (18)
- Age-Related Chronic Diseases and Alzheimer’s Disease in Texas: A Hispanic Focused Study (2021) (18)
- Mitochondria-Targeted Molecules as Potential Drugs to Treat Patients With Alzheimer's Disease. (2017) (17)
- Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges (2021) (16)
- Mitochondrial Abnormalities and Synaptic Damage in Huntington’s Disease: a Focus on Defective Mitophagy and Mitochondria-Targeted Therapeutics (2021) (16)
- Neural Underpinnings of Obesity: The Role of Oxidative Stress and Inflammation in the Brain (2020) (16)
- Protective Effects of BACE1 Inhibitory Ligand Molecules Against Amyloid Beta-Induced Synaptic and Mitochondrial Toxicities in Alzheimer's Disease. (2019) (16)
- Mitochondria-Targeted Small Peptide, SS31 Ameliorates Diabetes Induced Mitochondrial Dynamics in Male TallyHO/JngJ Mice (2020) (16)
- Selective Serotonin Reuptake Inhibitor Citalopram Ameliorates Cognitive Decline and Protects Against Amyloid Beta-induced Mitochondrial Dynamics, Biogenesis, Autopahgy, Mitophagy and Synaptic Toxicities in a Mouse Model of Alzheimer's Disease. (2021) (14)
- Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin (2007) (14)
- Elevated levels of MicroRNA-455-3p in the cerebrospinal fluid of Alzheimer's patients: a potential biomarker for Alzheimer's disease. (2021) (14)
- The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus (2021) (14)
- Cell cycle activation in p21 dependent pathway: An alternative mechanism of organophosphate induced dopaminergic neurodegeneration. (2017) (13)
- MicroRNA-455-3p improves synaptic, cognitive functions and extends lifespan: Relevance to Alzheimer's disease (2021) (13)
- Mitophagy enhancers against phosphorylated Tau-induced mitochondrial and synaptic toxicities in Alzheimer disease. (2021) (13)
- Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer's disease. (2017) (13)
- Hyperinsulinemia or Insulin Resistance: What Impacts the Progression of Alzheimer's Disease? (2019) (13)
- Are mitophagy enhancers therapeutic targets for Alzheimer’s disease? (2022) (12)
- Corrigendum: Mitochondria-targeted small molecule SS31: A potential candidate for the treatment of Alzheimer's disease [Human Molecular Genetics, 26, 8, (2017) (1483-1496)] doi: 10.1093/hmg/ddx052 (2017) (12)
- Protective effects of a small molecule inhibitor ligand against hyperphosphorylated tau-induced mitochondrial and synaptic toxicities in Alzheimer disease. (2021) (12)
- Amyloid Beta in Aging and Alzheimer’s Disease (2022) (12)
- Anti-brain Aging Effects of Small Molecule Inhibitor DDQ (2021) (11)
- Misfolded proteins, mitochondrial dysfunction, and neurodegenerative diseases. (2014) (11)
- Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies (2022) (11)
- Effects of Lipotoxicity in Brain Microvascular Endothelial Cells During Sirt3 Deficiency-Potential Role in Comorbid Alzheimer’s Disease (2021) (10)
- Mitophagy enhancers against phosphorylated Tau-induced mitochondrial and synaptic toxicities in Alzheimer disease (2021) (9)
- Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152: a phase 1, double-blind, randomised control trial (2020) (9)
- Altered glucose metabolism in Alzheimer's disease: Role of mitochondrial dysfunction and oxidative stress. (2022) (9)
- Healthy Immunity on Preventive Medicine for Combating COVID-19 (2022) (8)
- Are TallyHo Mice A True Mouse Model for Type 2 Diabetes and Alzheimer's Disease? (2019) (7)
- Can healthy lifestyle reduce disease progression of Alzheimer’s during a global pandemic of COVID-19? (2021) (7)
- Adenovirus 36 improves glycemic control and markers of Alzheimer's disease pathogenesis. (2019) (7)
- Protective effects of a small-molecule inhibitor DDQ against tau-induced toxicities in a transgenic tau mouse model of Alzheimer's disease. (2021) (7)
- Early Cellular, Molecular, Morphological and Behavioral Changes in the Humanized Amyloid-Beta-Knock-In Mouse Model of Late-Onset Alzheimer’s Disease (2022) (7)
- Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants (2022) (6)
- An Investigation of Short-Term Longitudinal Associations Between Handgrip Strength and Cardiovascular Disease Biomarkers Among Middle-Aged to Older Adults: A Project FRONTIER Study. (2020) (6)
- Role of Phosphorylated Tau and Glucose Synthase Kinase 3 Beta in Huntington's Disease Progression. (2019) (6)
- Current Issues in Chronic Diseases: A Focus on Dementia and Hypertension in Rural West Texans. (2019) (6)
- A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer’s Disease (2022) (6)
- Lifestyle and Risk Factors of Dementia in Rural West Texas. (2019) (5)
- Role of Nrf2 in aging, Alzheimer’s and other neurodegenerative diseases (2022) (5)
- The Role of Obesity and Diabetes in Dementia (2022) (5)
- Targeting mitochondrial bioenergetics as a promising therapeutic strategy in metabolic and neurodegenerative diseases (2022) (5)
- A transgenic mouse model for Alzheimer's disease has impaired synaptic gain but normal synaptic dynamics (2011) (5)
- Protective effects of antidepressant citalopram against abnormal APP processing and amyloid beta-induced mitochondrial dynamics, biogenesis, mitophagy and synaptic toxicities in Alzheimer’s disease (2021) (5)
- Current Status of Healthy Aging and Dementia Research: A Symposium Summary. (2019) (5)
- Rlip76: An Unexplored Player in Neurodegeneration and Alzheimer’s Disease? (2022) (4)
- RALBP1 in Oxidative Stress and Mitochondrial Dysfunction in Alzheimer’s Disease (2021) (4)
- A partial reduction of Drp1 improves cognitive behavior and enhances mitophagy, autophagy and dendritic spines in a transgenic tau mouse model of Alzheimer disease. (2021) (4)
- Synaptosome microRNAs regulate synapse functions in Alzheimer’s disease (2021) (4)
- Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein (2022) (4)
- A partial reduction of VDAC1 enhances mitophagy, autophagy, synaptic activities in a transgenic Tau mouse model (2022) (3)
- Mitochondria in Aging and Alzheimer's Disease: Focus on Mitophagy. (2023) (3)
- Reduced VDAC1, Maintained Mitochondrial Dynamics and Enhanced Mitochondrial Biogenesis in a Transgenic Tau Mouse Model of Alzheimer’s Disease (2022) (3)
- P1-227 Gene expression profiles of transcripts in amyloid precursor protein transgenic mice Up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease (2004) (3)
- Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimer’s disease (2021) (3)
- Potential role of E4orf1 protein in aging-associated impairment in glycemic control. (2019) (2)
- Garrison Institute on Aging: A New Hope for Elderly Individuals and Patients with Alzheimer's Disease. (2015) (2)
- GPR18-NAGly system in periaqueductal gray and chronic neuropathic pain. (2020) (2)
- Gene expression of endocannabinoid system in HIV-1-related neuropathic pain model. (2020) (2)
- Current status of stem cell research: An editorial. (2019) (2)
- Protective Effects of Chaya against Mitochondrial and Synaptic Toxicities in the Type 2 Diabetes Mouse Model TallyHO (2022) (2)
- Huntington’s Disease (2004) (2)
- Modulating autophagy and mitophagy as a promising therapeutic approach in neurodegenerative disorders. (2022) (1)
- Alzheimer Research Forum Live Discussion: A "Mitochondrial Cascade Hypothesis" for sporadic Alzheimer's disease (2005) (1)
- Corrigendum to "Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal" [Drug Discov. Today 22 (February (2)) (2017) 223-233]. (2019) (1)
- Current Status of Obesity: Protective Role of Catechins (2023) (1)
- Chronic pain in Alzheimer's disease: Endocannabinoid system (2022) (1)
- Dysregulated autophagy: A key player in the pathophysiology of type 2 diabetes and its complications. (2023) (1)
- Mitochondrial Dysfunctioning Induced by Hyperglycemia in the Liver Tissues of Diabetic Mice, TALLYHO/JngJ Strain and Ameliorative Action of a Small Peptide, SS31 (2021) (1)
- COVID-19 and its genomic variants: Molecular pathogenesis and therapeutic interventions (2022) (1)
- Targeting mitochondria as a potential therapeutic strategy against chemoresistance in cancer. (2023) (1)
- Regulation of retinoid mediated StAR transcription and steroidogenesis in hippocampal neuronal cells: Implications for StAR in protecting Alzheimer's disease. (2022) (1)
- Expression and Function of StAR in Cancerous and Non-Cancerous Human and Mouse Breast Tissues: New Insights into Diagnosis and Treatment of Hormone-Sensitive Breast Cancer (2023) (1)
- Improvement in Glycemic Control in Mice of Different Age Groups (2019) (1)
- Amyloid beta and mitochondrial dysfunction in the development and progression of Alzheimer's disease: Implications for mitochondrial therapeutics (2009) (1)
- Novel microRNA-455-3p mouse models to study Alzheimer’s disease pathogenesis (2021) (1)
- Role of RALBP1 in Oxidative Stress and Mitochondrial Dysfunction in Alzheimer’s Disease (2021) (1)
- Therapeutics of Alzheimer’s Disease: Recent Developments (2022) (1)
- Abnormal mitochondrial structural and functional changes caused by amyloid beta in Alzheimer's disease (2009) (0)
- Novel miRNA PC-5P-12969 in Ischemic Stroke (2019) (0)
- Rlip Depletion Alters Oncogene Transcription at Multiple Distinct Regulatory Levels (2022) (0)
- Targeting Mitochondria as a Novel Disease Modifying Therapeutic Strategy in Cancer (2021) (0)
- Mitochondrion is the direct site of abeta accumulation in Alzheimer's disease (2006) (0)
- Impaired mitochondrial bioenergetics and signaling pathways (2021) (0)
- Methods to Study Mitochondria: Techniques Used to Study the Effects of Age‐Related Diseases Including Alzheimer's (2023) (0)
- 9 Impact of COVID-19 on ischemic stroke condition (2023) (0)
- Translation of bioenergetics therapies (2021) (0)
- Mitochondrial miRNA as epigenomic signatures: Visualizing aging-associated heart diseases through a new lens (2023) (0)
- A partial reduction of Drp1 enhances mitophagy, autophagy, mitochondrial biogenesis, dendritic spines and synaptic activity in a transgenic Tau mouse model of Alzheimer disease (2021) (0)
- Progression of pre-rheumatoid arthritis to clinical disease of joints: Potential role of mesenchymal stem cells. (2023) (0)
- Stem cells in the treatment of Alzheimer's disease - Promises and pitfalls. (2023) (0)
- P4-169: Mitochondrially targeted antioxidant therapeutics in Alzheimer's disease (2008) (0)
- 3 Immune enhancers for COVID-19 (2023) (0)
- Synaptosome microRNAs regulate synapse functions in Alzheimer’s disease (2022) (0)
- Neuroinflammation and neovascularization in diabetic eye diseases (DEDs): identification of potential pharmacotherapeutic targets (2022) (0)
- 6 MicroRNAs and COVID-19 (2023) (0)
- 12 The effects of lifestyle in Alzheimer's disease during the COVID-19 pandemic (2023) (0)
- Protective function of StAR in amyloid-β accumulated hippocampal neurotoxicity and neurosteroidogenesis: Mechanistic insights into Alzheimer's disease. (2023) (0)
- Synaptosomal versus cytosolic microRNAs and synapse function in Alzheimer’s disease (2021) (0)
- Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias in African Americans: Focus on Caregivers (2023) (0)
- 1 COVID-19 and immunity an overview (2023) (0)
- Behavioral Evidence for a Tau and HIV-gp120 Interaction (2022) (0)
- Mitochondria-Targeted Small Peptide, SS31 Ameliorates Diabetes Induced Mitochondrial Dynamics in Male TallyHO/JngJ Mice (2020) (0)
- Insight into the liver dysfunction in COVID-19 patients: Molecular mechanisms and possible therapeutic strategies (2023) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With P. Hemachandra Reddy?
P. Hemachandra Reddy is affiliated with the following schools:
